RxDoctor Payments Data

Vincent Yavorek, MD

Family Medicine · Canandaigua, NYNPI 1558465237

Payments from drug & device makers

$1,444in general payments, 2019–2025

Across 115 payments — averaging $12.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$243
  • GSK$223
  • Novo Nordisk$220
  • AstraZeneca$149
  • Novartis$122
  • Merck$78
  • plus $409 from 10 others

What the payments were for

  • Food & beverage$1,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,444 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$161,137
Medicare patients
328
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,874$550,129
TrulicityDulaglutide237$202,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$63,034
JardianceEmpagliflozin174$49,021
CopaxoneGlatiramer Acetate16$45,994
IngrezzaValbenazine Tosylate11$42,062
JulucaDolutegravir/Rilpivirine11$41,219
XareltoRivaroxaban139$38,833
EntrestoSacubitril/Valsartan110$37,781
MyrbetriqMirabegron152$34,970
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr67$33,877
TradjentaLinagliptin110$28,572
AustedoDeutetrabenazine16$28,257
RexultiBrexpiprazole30$27,642
Metoprolol Succinate1,068$26,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$243$573,8331,939 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$223$127,938233 claims
Boehringer IngelheimJardiance, Tradjenta$45$77,593284 claims
Johnson & JohnsonXarelto$71$38,833139 claims
NovartisEntresto$122$37,781110 claims
Novo NordiskOzempic, Rybelsus$220$25,53228 claims
MerckJanuvia$78$12,67244 claims
AstraZenecaFarxiga$149$9,20331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →